Keywords: R&D resources, Alzheimer's disese,NeuroPerspective

Pharma’s “ill-considered” use of R&D resources in search for Alzheimer's therapeutics reviewed by NeuroPerspective

Article | 05 October 2011

A comprehensive review of Alzheimer's therapeutics, and a critical assessment of the pharmaceutical industry's ill-considered allocation of R&D ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in